Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Emcure Pharmaceuticals Reports 36% Profit Rise and 23% Revenue Growth in Q1 FY27

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Emcure Pharmaceuticals Reports 36% Profit Rise and 23% Revenue Growth in Q1 FY27

Analysed 6 Aug 2026·6 sources analysed·Hyderabad, India·Business
Emcure Pharmaceuticals Reports 36% Profit Rise and 23% Revenue Growth in Q1 FY27PreviousNext

Emcure Pharmaceuticals reported a 36.2% year-on-year rise in consolidated net profit to Rs 292.5 crore for Q1 FY27, with revenue increasing 22.8% to Rs 2,580.45 crore. Domestic revenue grew 10.2% to Rs 1,095.3 crore, while international business rose 34.2% to Rs 1,485.1 crore, accounting for 57.6% of total revenue. EBITDA increased 25.8% to Rs 508 crore, with improved margins. The company invested Rs 90.4 crore in research and development. Leadership changes include Satish Mehta becoming Chairman post-AGM.

Sentiment
69%
TBN's observations

First-hand measurement across 3 sources

We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 34/100.

Outlets measured: businessstandard, news18, freepressjournal. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 6 Aug 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (69/100)

Sentiment was consistent across outlets (58–68/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

freepressjournal broke this story on 6 Aug, 08:49 am. Other outlets followed.

6 Aug, 08:49 am3 sources · 64 min6 Aug, 09:53 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Emami Agrotech Enters Packaged Snacks Market with Rs 750 Crore Investment Plan
Next →
UK Expands Global Talent Visa to Include Over 100 Research Companies Including JLR
  1. 1
    freepressjournal6 Aug, 08:49 am
    Emcure Pharma Q1 PAT Rises 36 To 292.49 Crore, Revenue Up 22.8
  2. 2
    news186 Aug, 09:45 am
    Emcure Pharmaceuticals Q1 profit rises 36 pc at Rs 292.5 cr
  3. 3
    businessstandard6 Aug, 09:53 am
    Emcure Pharmaceuticals consolidated net profit rises 42.05 in the June 2026 quarter

Who's involved

Institutions and figures named across source coverage.

Government
National Commission for Minorities
Corporate
Emcure Pharmaceuticals LimitedEmcure PharmaceuticalsGennova Biopharmaceuticals

Story context

Category
Business
Location
Hyderabad, India
Sources analysed
6
Last analysed
6 Aug 2026
Key entities
Emcure PharmaceuticalsCroreIndian rupeeNet incomeChairpersonChief operating officerChief executive officerAnnual general meetingIndiaFiscal yearRevenueMumbai